AstraZeneca

1,470

SEK

+0.75 %

Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+0.75%

-9.37%

+1.62%

+1.62%

-6.46%

+1.2%

+17.69%

+65.35%

+7,943.56%

AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and marketing of prescription drugs, primarily for the treatment of diseases in the areas of therapy that affect the respiratory tract, cardiovascular / metabolism, and cancer. In addition to its main operations, the company is also active in autoimmunity, neuroscience, and infection. AstraZeneca is active in all global regions and is headquartered in Cambridge.

Market cap

2.28T SEK

Turnover

366.79M SEK

Revenue

596.39B

EBIT %

18.5 %

P/E

29.36

Dividend yield-%

2.33 %

Financial calendar

11/4

2025

General meeting '25

29/4

2025

Interim report Q1'25

All

Press releases

ShowingAll content types

Press releaseyesterday

AstraZeneca: AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

Press releaseyesterday

AstraZeneca: Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma

Press releaseyesterday

AstraZeneca: Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release3/27/2025, 7:06 AM

AstraZeneca: Alexion data presented at the 2025 AAN Annual Meeting highlight advancements in improving care for rare neurological diseases

Press release3/25/2025, 7:05 AM

AstraZeneca: New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Press release3/21/2025, 11:09 AM

AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing

Press release3/17/2025, 7:26 AM

AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets

Press release3/17/2025, 7:20 AM

AstraZeneca: Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial

Press release3/17/2025, 7:12 AM

AstraZeneca: Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer

Press release3/17/2025, 7:03 AM

AstraZeneca to acquire EsoBiotec to advance cell therapy ambition

Regulatory press release3/12/2025, 8:42 AM

Finansinspektionen: Flaggningsmeddelande i AstraZeneca PLC

Press release3/7/2025, 11:00 AM

AstraZeneca: Notice of Annual General Meeting

Press release3/7/2025, 7:02 AM

AstraZeneca: Imfinzi-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Press release3/3/2025, 7:06 AM

AstraZeneca: Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer

Press release3/2/2025, 7:00 AM

AstraZeneca: Positive results from the Tezspire Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

Regulatory press release2/28/2025, 1:06 PM

AstraZeneca: Enhertu recommended in EU in post-ET breast cancer

Press release2/28/2025, 1:00 PM

AstraZeneca: Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy

Press release2/26/2025, 7:03 AM

AstraZeneca: Camizestrant improved PFS in 1L HR+ breast cancer

Press release2/19/2025, 7:12 AM

AstraZeneca: Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission

Press release2/18/2025, 11:00 AM

AstraZeneca: Annual Financial Report

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.